Evidence map›Paper›PMID 42244555›Full record

ArticlebioRxiv : the preprint server for biology2026

Prioritizing peptides for targeted mass spectrometry experiments using deep learning.

Shreyash Sonthalia, Priank Dasgupta, Chris Hsu, Bo Wen, Michael J MacCoss, William Stafford Noble

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shreyash SonthaliaDepartment of Genome Sciences, University of Washington.ORCID 0000-0003-1912-7901
Priank DasguptaPaul G. Allen School of Computer Science and Engineering, University of Washington.
Chris HsuDepartment of Genome Sciences, University of Washington.ORCID 0000-0002-0846-6126
Bo WenDepartment of Genome Sciences, University of Washington.ORCID 0000-0003-2261-3150
Michael J MacCossDepartment of Genome Sciences, University of Washington.ORCID 0000-0003-1853-0256
William Stafford NobleDepartment of Genome Sciences, University of Washington.ORCID 0000-0001-7283-4715

Funding

Seattle Quant: A Resource for the Skyline Software EcosystemR24GM141156 · NIGMS · UNIVERSITY OF WASHINGTON · PI Michael MacCoss · 2021 to 2026
$6.7M
Quantifying proteins in plasma do democratize personalized medicine for patients with type 1 diabetesU01DK137097 · NIDDK · UNIVERSITY OF WASHINGTON · PI ANDREW N HOOFNAGLE, Michael MacCoss · 2023 to 2026
$3.4M
NIDDK NIH HHS U01 DK137097NIGMS NIH HHS R24 GM141156
6 · The paper itself

Abstract

One critical step in any targeted mass spectrometry experiment is selecting, from each protein of interest, a small number of peptides that respond well in the mass spectrometer and can serve as reliable proxies for protein quantification. Existing methods select target peptides either by relying on prior empirical measurements, limiting their applicability to previously observed peptides, or using machine learning to predict peptide behavior from sequence alone. However, current machine learning tools suffer from various limitations, including using detectability as an indirect proxy for intensity, relying on small training sets, or ignoring the precursor charge state. In this study, we introduce Bromo, a transformer-based deep learning model that ranks peptide precursors from a given protein by their relative response, taking charge state into account. Trained on millions of annotated peptide pairs derived from large-scale, publicly available data-independent acquisition mass spectrometry data, Bromo consistently outperforms existing sequence-based methods across diverse, independent datasets. Furthermore, we show that finetuning Bromo on experiment-specific data can account for differences in sample preparation, sample matrix, and instrument platform, all of which influence which peptides serve as optimal targets. This adaptability makes Bromo a practical tool for selecting target peptides for selected reaction monitoring and parallel reaction monitoring assay development across a wide range of experimental conditions.

Identifiers

PMID42244555
PMCPMC13232108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.